3D Systems Corporation (NYSE:DDD) heads into an Aug. 3 Q2 report with guidance roughly matching analyst expectations for ~$93.8M revenue and a slight loss, while scoring FDA clearance for a patient-specific 3D MAC Titanium Cranial Plate and partnering with Elmet to fast-track aerospace part production.
Previous Week Recap
- 3D Systems Q2 2026 Guidance: 3D Systems (DDD) will report Q2 2026 results Aug 3. Analysts forecast ~ $93.8M revenue (down ~1.1% YoY) and $0.05 loss per share; company guided revenue $93–95M and EBITDA -$2M to $93M.
- FDA Premarket Clearance For 3D MAC Titanium Cranial Plate: 3D Systems (DDD) won FDA premarket clearance for its 3D MAC Titanium Cranial Plate, a patient-specific implant developed with Defense Health Agency and Walter Reed for traumatic head injuries.
- Elmet Partnership For DMP Flex 350 Triple: 3D Systems (DDD) partners with Elmet to deploy the DMP Flex 350 Triple for rapid production of aerospace and hypersonic parts; part qualification expected in months, then NASA 6030 certification.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.